Cochrane Library

Cochrane Database of Systematic Reviews

Steroids for acute spinal cord injury (Review)

Bracken MB

Bracken MB.
Steroids for acute spinal cord injury.
Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD001046.
DOI: 10.1002/14651858.CD001046.pub2.

www.cochranelibrary.com

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER 1
ABSTRACT 1
PLAIN LANGUAGE SUMMARY 2
BACKGROUND 3
OBJECTIVES 3
METHODS 3
RESULTS 4
DISCUSSION 5
AUTHORS' CONCLUSIONS 5
ACKNOWLEDGEMENTS 6
REFERENCES 7
CHARACTERISTICS OF STUDIES 8
DATA AND ANALYSES 15
Analysis 1.1. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients. 17
Analysis 1.2. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 2 Motor function at six weeks, six months and one year: <8 hours to treatment. 17
Analysis 1.3. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients. 18
Analysis 1.4. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment. 18
Analysis 1.5. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 5 Touch sensation at six weeks, six months and one year: all patients. 18
Analysis 1.6. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment. 19
Analysis 1.7. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 7 All-cause mortality, <210 days. 19
Analysis 1.8. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 8 Wound infection at six weeks. 19
Analysis 1.9. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 9 GI haemorrhage at six weeks. 20
Analysis 1.10. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 10 Sepsis at six weeks. 20
Analysis 2.1. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients. 21
Analysis 2.2. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 2 Motor function at six weeks, six months, and one year: <8 hours to treatment. 22
Analysis 2.3. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients. 23
Analysis 2.4. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment. 23
Analysis 2.5. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 5 Touch sensation at six weeks, six months and one year: All patients. 24
Analysis 2.6. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment. 24
Analysis 2.7. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 7 All-cause mortality <180 days. 25
Analysis 2.8. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 8 Wound infection at 6 weeks. 25
Analysis 2.9. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 9 GI haemorrhage at 6 weeks. 25
Analysis 3.1. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 1 Motor function at six weeks, six months and one year: all patients. 27
Analysis 3.2. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 2 Motor function at six weeks, six months and one year: 3-8 hours to treatment. 27
Analysis 3.3. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients. 28
Analysis 3.4. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 4 Pinprick sensation at six weeks, six months and one year: 3-8 hours to treatment. 28
Analysis 3.5. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 5 Touch sensation at six weeks, six months and one year: all patients. 28

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 3.6. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 6 Touch sensation at six weeks, six months and one year: 3-8 hours to treatment. 29
Analysis 3.7. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 7 Severe pneumonia at 6 weeks. 29
Analysis 3.8. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 8 Severe sepsis at 6 weeks. 29
Analysis 3.9. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 9 Mortality at 1 year. 29
Analysis 4.1. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 1 One-year motor function improvement score. 30
Analysis 4.2. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 2 One-year pinprick sensation improvement score. 30
Analysis 4.3. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 3 One-year touch sensation improvement score. 30
APPENDICES 30
FEEDBACK 33
WHAT'S NEW 36
HISTORY 36
CONTRIBUTIONS OF AUTHORS 37
DECLARATIONS OF INTEREST 37
SOURCES OF SUPPORT 37
NOTES 37
INDEX TERMS 37

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

[Intervention Review]

Steroids for acute spinal cord injury

Michael B Bracken[1]

[1]Department of Epidemiology & Public Health, Yale School of Medicine, New Haven, CT, USA

Contact address: Michael B Bracken, Department of Epidemiology & Public Health, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06501, USA. michael.bracken@yale.edu.

Editorial group: Cochrane Injuries Group
Publication status and date: Edited (no change to conclusions), comment added to review, published in Issue 9, 2018.

Citation: Bracken MB. Steroids for acute spinal cord injury. *Cochrane Database of Systematic Reviews* 2012, Issue 1. Art. No.: CD001046. DOI: 10.1002/14651858.CD001046.pub2.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Acute spinal cord injury is a devastating condition typically affecting young people, mostly males. Steroid treatment in the early hours after the injury is aimed at reducing the extent of permanent paralysis during the rest of the patient's life.

Objectives

To review randomized trials of steroids for human acute spinal cord injury.

Search methods

We searched the Cochrane Injuries Group's Specialised Register (searched 02 Aug 2011), The Cochrane Central Register of Controlled Trials 2011, issue 3 (The Cochrane Library), MEDLINE (Ovid) 1948 to July Week 3 2011, EMBASE (Ovid) 1974 to 2011 week 17, ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to Aug 2011, ISI Web of Science: Conference Proceedings Citation Index- Science (CPCI-S) 1990 to Aug 2011 and PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 04 Aug 2011) for records added to PubMed in the last 90 days). Files of the National Acute Spinal Cord Injury Study (NASCIS) were reviewed (NASCIS was founded in 1977 and has tracked trials in this area since that date). We also searched the reference lists of relevant studies and previously published reviews.

Selection criteria

All randomized controlled trials of steroid treatment for acute spinal cord injury in any language.

Data collection and analysis

One review author extracted data from trial reports. Japanese and French studies were found through NASCIS and additional data (e.g. SDs) were obtained from the original study authors.

Main results

Eight trials are included in this review, seven used methylprednisolone. Methylprednisolone sodium succinate has been shown to improve neurologic outcome up to one year post-injury if administered within eight hours of injury and in a dose regimen of: bolus 30mg/kg over 15 minutes, with maintenance infusion of 5.4 mg/kg per hour infused for 23 hours. The initial North American trial results were replicated in a Japanese trial but not in the one from France. Data was obtained from the latter studies to permit appropriate meta-analysis of all three trials. This indicated significant recovery in motor function after methylprednisolone therapy, when administration commenced within eight hours of injury. A more recent trial indicates that, if methylprednisolone therapy is given for an additional 24 hours (a total of 48 hours), additional improvement in motor neurologic function and functional status are observed. This is particularly observed if treatment cannot be started until between three to eight hours after injury. The same methylprednisolone therapy has been found effective in whiplash injuries. A modified regimen was found to improve recovery after surgery for lumbar disc disease. The risk of bias was low in

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

the largest methyprednisolone trials. Overall, there was no evidence of significantly increased complications or mortality from the 23 or 48 hour therapy.

Authors' conclusions

High-dose methylprednisolone steroid therapy is the only pharmacologic therapy shown to have efficacy in a phase three randomized trial when administered within eight hours of injury. One trial indicates additional benefit by extending the maintenance dose from 24 to 48 hours, if start of treatment must be delayed to between three and eight hours after injury. There is an urgent need for more randomized trials of pharmacologic therapy for acute spinal cord injury.

PLAIN LANGUAGE SUMMARY

Steroids for acute spinal cord injury

Every year, about 40 million people worldwide suffer a spinal cord injury. Most of them are young men. The results are often devastating. Various drugs have been given to patients in attempts to reduce the extent of permanent paralysis. Steroids have probably been used more for this purpose than any other type of drug. The review looked for studies that examined the effectiveness of this treatment in improving movement and reducing the death rate. Nearly all the research, seven trials, has involved just one steroid, methylprednisolone. The results show that treatment with this steroid does improve movement but it must start soon after the injury has happened, within no more than eight hours. It should be continued for 24 to 48 hours. Different dose rates of the drug have been given and the so-called high-dose rate is the most effective. The treatment does not, however, give back the patient a normal amount of movement and more research is necessary with steroids, possibly combining them with other drugs.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

BACKGROUND

It is estimated that acute spinal cord injury affects some 40 per million people each year (Bracken 1981), although estimates of incidence may vary considerably between countries. In all countries this is an injury affecting primarily young males, typically aged 20 to 35. (A 4:1 male to female ratio is common.) The permanent paralysis that follows leads to major disability, a shorter life expectancy and significant economic cost (Berkowitz 1992). Animal experimentation with pharmacologic therapy for acute spinal cord injury started in the late 1960s (Ducker 1969), became more common in the 1970s and led, in the USA, to the first National Acute Spinal Cord Injury Study (NASCIS 1) started in 1979 and completed in 1984 (Bracken 1984/85). As far as can be ascertained, this was the first randomized trial of any therapeutic modality for all aspects of spinal cord injury. The second National Acute Spinal Cord Injury Study followed (Bracken 1990/93). A multicenter trial from Japan (Otani 1994) and a single center trial from France (Petitjean 1998) both evaluated one of the treatment arms of NASCIS 2 which represents the first replication of a trial in this area. The third NASCIS trial has been reported (Bracken 1997/98).

OBJECTIVES

To assess the effects of steroids for acute spinal cord injury.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled trials.

Types of participants

Patients admitted to medical centers with a diagnosis of acute spinal cord injury. This review includes trials of patients with whiplash injury and those being treated for lumbar disc disease, because of the possibility of spinal cord injury with these conditions. Different trials impose their own eligibility restrictions: for example, excluding patients of young age, with gunshot injuries or with severe co-morbidity – particularly severe head trauma. Most acute spinal cord injury trials exclude patients with only nerve root damage or cauda equina.

Types of interventions

The review is restricted to treatment with steroids.

Types of outcome measures

Neurologic recovery of motor function at six weeks, six months and one year, mortality and incidence of infections form the primary outcome measures. Recovery of pinprick and light touch sensation or other sensory measures are not formally evaluated in this review.

Search methods for identification of studies

The search for trials was not restricted by language, date or publication status (i.e. published or unpublished).

Electronic searches

We searched the following electronic databases;

- Cochrane Injuries Group Specialised Register (searched 02 Aug 2011);
- Cochrane Central Register of Controlled Trials 2011, issue 3 (The Cochrane Library);
- MEDLINE (Ovid) 1948 to July Week 3 2011;
- EMBASE (Ovid)1974 to 2011 week 17;
- ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to Aug 2011;
- ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S) 1990 to Aug 2011;
- PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 04 Aug 2011: records added to PubMed in the last 90 days).

The full search strategies can be found in Appendix 1.

Searching other resources

We checked the reference lists of all included studies and previously published relevant reviews. We contacted trial authors in the field for information on any further studies they may be aware of, whether published, unpublished or ongoing. The National Acute Spinal Cord Injury Study (NASCIS) was also consulted for relevant trials, the organization was founded in 1977 and has tracked trials in this area to the present date.

Data collection and analysis

The Injuries Group Trials Search Co-ordinator ran the searches. Search results were then transferred to the author who assessed them for eligibility and extracted data where appropriate.

The quality of trials was assessed using methodology developed by the Cochrane Neonatal Review Group. This considers whether the intervention was blinded, whether people evaluating outcome are blinded, how many patients were followed up and the quality of the randomization process. More details can be found in Sinclair 1992.

Mortality and more prevalent clinical sequelae have been reported for each trial in the present review. The different treatment arms under study, as well as variation in the definition of sequelae, preclude any analysis across different trials, except for a comparison of 180-day mortality in the two trials using very-high-dose methylprednisolone.

In the French trial (Petitjean 1998), additional information provided by the trial author has permitted calculation of bilateral neurologic improvement scores for motor function, and pinprick and touch sensation at one year. Standard deviations for the change scores were imputed using the method described in the Cochrane Handbook 3.02 (1997, pp 213-7) (Follmann 1992). Additional information has also been obtained for the Japanese trial (Otani 1994) to permit calculation of motor function improvement, data from the right side are used. Data from the NASCIS trials (Bracken 1984/85; Bracken 1990/93; Bracken 1997/98) uses neurologic improvement scores from the right side of the body, which is also adjusted for each patient's baseline neurologic function, and so is identical to the change scores reported in the original publications. In the NASCIS trials, when right-side data was unavailable (due to casts or amputation) the left-side score for that data point was substituted. The standard deviations for the subgroup analyses were derived from the total change score for the same parameter at the same follow-up period.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

The weighted mean difference of neurologic improvement scores was computed with 95% confidence intervals (CIs). For mortality and morbidity, the relative risk (RR) and 95% CIs were computed. A fixed-effect model was assumed. The heterogeneity test was examined to assist in decisions whether or not to produce typical estimates of effect.

RESULTS

Description of studies

All trials were randomized double-blind placebo or active drug controlled trials, except Otani 1994 and Petitjean 1998, which used a randomized control group of patients who did not receive methylprednisolone.

The NASCIS and Japanese trials used an improvement score reflecting neurologic status at follow-up, as changed from the same status measured in the emergency department. The French trial used the final bilateral total ASIA score which is very similar to NASCIS scoring (which has one additional segment) but did not compute a change score. The primary parameters were motor function and pinprick and light touch sensation. This review focuses on motor recovery scores. In the NASCIS 3 trial the functional independence measure (FIM) was also evaluated. Morbidity and mortality were examined in most trials. NASCIS used data from the right side of the body to evaluate neurologic outcomes in all trials and this review used right side data from Otani 1994 for comparison. The trial of whiplash injury used measures of disability, sick days and a sick-leave profile. The trial of lumbar disc disease measured relief of back and radicular pain and length of hospital stay.

A small trial by Matsumoto 2001 only assessed complications after methylprednisolone therapy and no efficacy data were produced.

Methylprednisolone sodium succinate (MPSS) is the most widely studied therapy and formed at least one arm in all three NASCIS studies. It is the only therapy to have been replicated in more than one trial. All trials have imposed some therapeutic window between injury and starting administration of treatment. This window has been shortened to initiating therapy within eight hours in the more recent trials, as evidence has accumulated that pharmacologic therapies appear to require rapid administration if they are to be effective.

Trials are described in more detail in the 'Characteristics of included studies' table.

Risk of bias in included studies

Random sequence generation (selection bias)

Six studies generated the randomisation sequence adequately and were at low risk of bias; in two studies the method for generating the randomisation sequence was unclear because it was not described.

Allocation

Six studies had adequate concealment of the randomisation sequence and are at low risk of bias; in two studies it was unclear if the allocation was concealed.

Blinding

Five studies had adequate performance and detection blinding but three were at high risk due to being unblinded.

Incomplete outcome data

Six studies were at low risk of bias and two were unclear.

Selective reporting

Four studies had adequate reporting and four were unclear.

Other potential sources of bias

Three studies had low risk of other reporting biases and four were unclear.

Effects of interventions

Moderate versus low-dose methylprednisolone, 10-day regimen (Comparison 01)
One trial considered this therapeutic regimen (Bracken 1984/85). When the overall results for this trial are considered, there is no difference in the neurologic outcome scores at six weeks, six months or one year (Outcomes 01, 03, 05). Because of subsequent interest in the eight hour therapeutic window for commencing therapy, an ex-post-facto analysis of patients who initiated therapy within this time window is examined in this review (Outcomes 02, 04 ,06). There is a trend for patients treated with the high-dose regimen to recover more than those on the low-dose regimen at all three follow-up periods and on all three neurologic parameters. None of these changes reached the nominal $P < 0.05$ level of statistical significance.

All-cause mortality, wound infection, GI hemorrhage and sepsis were examined. Only wound infection was elevated in the high-dose regimen (RR = 3.50, 95% CI 1.18 to 10.41) (Outcomes 07 to 10).

High-dose methylprednisolone versus placebo or none, 24-hour regimen (Comparison 02)
Three trials are examined for this comparison (Bracken 1990/93, Otani 1994, Petitjean 1998). When the overall results are considered for motor function (Outcome 01) there is no effect of methylprednisolone. For the NASCIS 2 trial (Bracken 1990/93) an a-priori hypothesis was proposed to examine patients treated early versus late. The eight hour window was established based on it being close to the median time to treatment. The other two trials restricted patient eligibility to entry within eight hours of injury. When the analysis is restricted to patients treated within the eight hour window (Outcome 02), high-dose methylprednisolone resulted in greater motor function recovery at six weeks, six months and the final outcome (which differed among the trials as being 6 months or one year) (WMD = 4.06, 95% CI 0.58 to 7.55).

In one trial, pinprick sensation was significantly improved in all patients at six months (WMD = 3.37, 95% CI 0.74 to 6.00) but not at one year (Outcome 03). Among patients treated within eight hours these differences were enhanced at six months but were not different at one year (Outcome 04). Light touch sensation showed a similar pattern of results as pinprick (Outcomes 05 and 06).

All cause mortality (3 trials), wound infection (1 trial) and GI hemorrhage (2 trials) did not differ between the two comparison groups (Outcomes 07 to 09).

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

High-dose methylprednisolone for 48 versus 24 hours (Comparison 03)

One trial contributed to this analysis (Bracken 1997/98). There was a trend for greater motor function improvement in the 48-hour treated patients (Outcome 01) but at none of the follow-up periods did these differences reach statistical significance. In this trial, an a priori hypothesis proposed to examine patients initiating therapy early versus late within the overall eight hour window of eligibility. The median of three hours was selected for a cut-off point. Patients treated within three hours after injury did not differ in their recovery from 24 or 48-hour methylprednisolone (Bracken 1997/98). Patients treated within 3 to 8 hours improved more motor function if treated with 48-hour methylprednisolone (Outcome 02). No meaningful differences were observed for pinprick or touch sensation in the full analysis or in those treated at 3 to 8 hours at any of the follow-up periods (Outcomes 03 to 06).

Severe pneumonia and severe sepsis tended to be elevated in the 48-hour treated patients but overall mortality at one year was not (Outcomes 07 to 09).

High-dose methylprednisolone for 23 hours versus nimodipine for seven days (Comparison 04)

One trial contributed to this analysis (Petitjean 1998). No meaningful observations could be made from these comparisons because of very high variability in the data (Outcomes 01 to 03).

Other trials

In the whiplash trial (Pettersson 1998), the identical regimen of methylprednisolone to that administered in NASCIS 2 was found to result in fewer disabling symptoms (P = 0.047), fewer sick days (P = 0.01) and a healthier sick leave profile (P = 0.003) at six months post injury.

For patients treated with methylprednisolone at the time of their discectomy for lumbar disc disease, their hospital stay was significantly shorter than patients not so treated (1.4 versus 4.0 days, P = 0.0004) (Glasser 1993).

DISCUSSION

Trials of steroid therapy for acute spinal cord injury are rare. Only eight trials were found in the literature, seven of methylprednisolone. Clearly, there is a critical need for more randomized trials to evaluate many aspects of management for this injury. The relatively low incidence of spinal cord injury may explain why trials have lagged behind many other clinical specialties but the fact that two large multi-center trials were concurrently underway in the US during the early 1990s indicates that there has been, and will continue to be, opportunities for more trials in this area.

The first NASCIS trial (Bracken 1984/85) did not find any beneficial effect of methylprednisolone given at 1g per day for 10 days. In analyses completed for this review, which stratify the patients according to those treated within 8 hours, there is some modest evidence of potential benefit in patients treated early.

The second NASCIS trial (Bracken 1990/93) found significantly increased neurologic recovery among patients treated with very-high-dose methylprednisolone within eight hours of injury. This treatment has become a standard therapy in many countries. As shown by this review, additional trials (Otani 1994; Petitjean 1998) have only slightly moderated the conclusion that this regimen offers some neurologic benefit to some patients. This treatment regimen does not appear to be related to any significant increased risk of medical complication. A third NASCIS trial (Bracken 1997/98) contrasted the NASCIS 2 treatment with methylprednisolone with an extended 48-hour regimen which was shown to further improve motor function and functional outcomes (not examined in this review), particularly if initiation of therapy could not start until three to eight hours post injury. The pharmacologic rationale for the effect of methylprednisolone and a review of the animal literature has been provided by Hall 1992.

The additional trials of Glasser 1993 and Pettersson 1998 provide some supportive evidence for a role for methylprednisolone in recovery from acute spinal cord injury, although it is likely that much of the recovery in those trials was due to nerve root function rather than spinal cord improvement per se.

A systematic review of almost 2500 patients in 51 trials of the use of high-dose methylprednisolone versus placebo or nothing by Sauerland 2000 provides further reassurance of safety. High-dose methylprednisolone was defined as any intravenous dose exceeding 15 mg/kg or 1g MPSS given as a single or repeated dose within a maximum of three days and discontinued afterwards. The trials included trauma and elective spine surgery. No evidence was found for any increased risk of gastro-intestinal bleeding (RD = 0.3%, P = 0.4), wound complication (RD = 1%, P = 0.2), pulmonary complications (for which MPSS was significantly protective RD = -3.5%, P = 0.003) or death (also moderately protective RD = -0.9%, P = 0.10). No evidence of harm was found when spine surgery alone was considered. These results are discussed more in Bracken 2001. In another study long-term follow-up of avascular necrosis after high-dose MPSS for acute spinal cord injury, diagnosed by MRI of femoral and humeral heads assessed blind to therapy, failed to find any increased risk (Wing 1998).

Only some of the analyses in this review have been adjusted for any potential imbalances in baseline factors observed at randomization, even though some imbalances were reported. However, none of the results reported in this review for any of the individual trials appear to be inconsistent with the data reported in the original trial reports.

AUTHORS' CONCLUSIONS

Implications for practice

Methylprednisolone sodium succinate has been shown to enhance sustained neurologic recovery in a phase three randomized trial, and to have been replicated in a second trial. Therapy must be started within eight hours of injury using an initial bolus of 30 mg/kg by IV for 15 minutes followed 45 minutes later by a continuous infusion of 5.4mg/kg/hour for 24 hours. Further improvement in motor function recovery has been shown to occur when the maintenance therapy is extended for 48 hours. This is particularly evident when the initial bolus dose could only be administered three to eight hours after injury.

Implications for research

Methylprednisolone treatment improves neurologic recovery but is unlikely to bring a return to normal function unless there is minimal initial deficit. More research is needed to examine whether different MPSS protocols would achieve even more recovery. It

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

is likely that future trials will be able to examine concurrent pharmacologic therapies (sometimes called drug cocktails) or sequential therapies which operate on different aspects of the secondary injury processes ranging from early neuron protection to nerve regeneration in the chronic patient.

ACKNOWLEDGEMENTS

Thanks to Peter Smith for his help with translating the Petitjean paper and Frances Bunn for technical assistance. Thanks to Dr Petitjean for providing additional information about the French trial.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

REFERENCES

References to studies included in this review

Bracken 1984/85 *{published data only}*

* Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. Efficacy of methylprednisolone in acute spinal cord injury. *Journal of the American Medical Association* 1984;**251**:45-52.

Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, et al. Methylprednisolone and neurological function one year after spinal cord injury. *Journal of Neurosurgery* 1985;**63**:704-13.

Bracken 1990/93 *{published data only}*

Bracken MB. Pharmacological treatment of acute spinal cord injury: current status and future prospects. *Paraplegia* 1992;**30**:102-7.

Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone on recovery of segmental and long-tract neurological function in NASCIS 2. *Journal of Neurosurgery* 1993;**79**:500-7.

Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1 year follow-up data. *Journal of Neurosurgery* 1992;**76**:23-31.

* Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. *New England Journal of Medicine* 1990;**322**:1405-11.

Duh M-S, Shepard MJ, Wilberger JE, Bracken MB. The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment. *Neurosurgery* 1994;**35**:240-9.

Leake G, Pascale VJ, Alfano SL, Bracken MB. Methlyprednisone for acute spinal cord injury. *American Journal of Hospital Pharmacy* 1990;**47**:1977.

Shepherd MJ, Bracken MB. The effect of methylprednisolone, naloxone, and spinal cord trauma on four liver enzymes: observations from NASCIS 2. *Paraplegia* 1994;**32**:236-45.

Bracken 1997/98 *{published data only}*

* Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. *Journal of the American Medical Association* 1997;**277**:1597-604.

Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. *Journal of Neurosurgery* 1998;**89**:699-706.

Glasser 1993 *{published data only}*

Glasser RS, Knego RS, Delashaw JB, Fessler RG. The perioperative use of corticosteroids and bupivacaine in the management of lumbar disc disease. *Journal of Neurosurgery* 1993;**78**:383-7.

Matsumoto 2001 *{published data only}*

Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. *Spine* 2001;**26**(4):426-30.

Otani 1994 *{published data only}*

Otani K. Functional recovery: focus on upper and lower limbs (translation of Japanese). *Journal of the Japanese Paraplegia Medicine Association* 1995;**8**:80-1.

* Otani K, Abe H, Kadoya S, et al. Beneficial effect of methylprednisolone sodium succinate in the treatment of acute spinal cord injury (translation of Japanese). *Sekitsui Sekizui J* 1994;**7**:633-47.

Yokota H, Kawai M, Kato K, et al. Significance of methylprednisolone therapy in acute spinal cord injury with special reference to short term follow-up (translation of Japanese). *Journal of the Japanese Association of Acute Medicine* 1995;**6**:349-54.

Petitjean 1998 *{published data only}*

Petitjean ME, Pointillart V, Dixmerias F, Wiart L, Sztark F, Lassie P, Thicoipe M, Dabadie P. Traitement medicamenteux de la lesion medullaire traumatique au stade aigu. *Annales françaises d'anesthèsie et de rèanimation* 1998;**17**:115-22.

Pettersson 1998 *{published data only}*

Pettersson K, Toolanen G. High dose methylprednisolone prevents extensive sick-leave after whiplash injury. A prospective randomized double-blind study. *Spine* 1998;**23**:984-9.

References to studies excluded from this review

Kiwerski 1992 *{published data only}*

Kiwerski J. Zastosowanie dexametazonu w leczeniu uszkodzen rdzenia kregowego we wczesnym okresie pourazowym. *Neur Neurochir Pol* 1992;**26**:518-27.

Pointillart 2000 *{published data only}*

Pointillart V, Petitjean ME, Vital JM, Lassie P, Thicoipe M, Dabadie P. Pharmacological therapy of spinal cord injury during the acute phase. *Spinal Cord* 2000;**38**:71-6.

Yokota 1995 *{published data only}*

Yokota H, Kawai M, Kato K, Mashiko K, Yamamoto Y, Henmi H, Otsuka T. Significance of methylprednisolone therapy in acute spinal cord injury with special reference to short-term follow-up. *Journal of the Japanese Association of Acute Medicine* 1995;**6**:349-54.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Additional references

Berkowitz 1992

Berkowitz M, Harvey C, Greene CG, Wilson SE. The economic consequences of traumatic spinal cord injury. New York: Demos Publications, 1992.

Bracken 1981

Bracken MB, Freeman DH, Hellenbrand K. Incidence of acute traumatic hospitalized spinal cord injury in the United States 1970-1977. *American Journal of Epidemiology* 1981;**133**:615-22.

Bracken 2001

Bracken MB. Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. *Spine* 2001;**26**:S47-55.

Ducker 1969

Ducker TB, Hamit HF. Experimental treatments of acute spinal cord injury. *Journal of Neurosurgery* 1969;**30**:693-722.

Follmann 1992

Follmann D, Elliott P, Cutler J. Variance imputation for overviews of clinical trials with continuous response. *Journal of Clinical Epidemiology* 1992;**45**:769-73.

Hall 1992

Hall ED. The neuroprotective pharmacology of methylprednisolone. *Journal of Neurosurgery* 1992;**76**:13-22.

Sauerland 2000

Sauerland S, Nagelschmidt M, Mallman P, et al. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematc review. *Drug Safety* 2000;**55**:452-3.

Sinclair 1992

Sinclair JC, Bracken MB (eds). Effective care of the newborn infant. Oxford: Oxford University Press, 1992:p9.

Wing 1998

Wing PC, Nance P, Connell DG, et al. Risk of avascular necrosis following short term megadose methylprednisolone treatment. *Spinal Cord* 1998;**36**:633-6.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Bracken 1984/85

Methods	Multi-center (n=9) double-blind randomized trial. After ascertaining eligibility a 24-hour telephone number called to learn which uniquely numbered drug packet (already delivered to the hospital) should be used. Each hospital given block of 6 (3 patients in each treatment arm). Double dummy technique used to mask study drugs.
Participants	In all, 330 patients randomized within 48h of injury (165 to each treatment), 24 patients excluded from analysis for specified reasons (table 2). In this review morbidity and mortality use all randomized patients in denominator but conclusions remain unchanged. This review delineates those patients treated within 8h of injury.
Interventions	Treatment arm 1: (n=165) Immediately after randomization a loading dose of 100 mg MPPS and 25 mg every six hours thereafter for 10 days. Treatment arm 2: (n=165) As above but 1000 mg LD and 250 mg thereafter. LD administered over 10 minutes. Maintenance doses administered using fluid administration set, either directly or through IV.
Outcomes	Neurological examinations and clinical status examined six weeks, six months and one year after injury. Neuroexam included motor function and pinprick and light touch sensation, all measured categorically and as continuous scales. All outcomes assessed blind. Clinical outcomes included: urinary tract infection, pneumonia, decubitus, gastrointestinal hemorrhage, wound infection, sepsis, arrythmia, thrombophlebitis, pulmonary embolus, paralytic ileus, congestive heart failure, myocardial infarction, angina pectoris and death < 14 days, 15-28 days and at 1 year.
Notes	Historical note: This may be the first randomized controlled trial of any treatment modality for acute spinal cord injury. This trial is often referred to as NASCIS 1 (The first National Acute Spinal Cord Injury Study).

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bracken 1984/85 *(Continued)*

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	See Methods
Allocation concealment (selection bias)	Low risk	See Methods
Blinding of participants and personnel (performance bias) All outcomes	Low risk	patients, caregivers and statistical analysts blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Patients, caregivers blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	92% follow-up at 6 weeks and 65% at 6 months, 100% survival analysis
Selective reporting (reporting bias)	Low risk	Outcomes prespecified in protocol
Other bias	Low risk	Subgroups prespecified in protocol

Bracken 1990/93

Methods	Multi-center (n=10) double-blind randomized trial. Three treatment arms in blocks of 9 (3 each arm) per center. Randomized by central telephone. Double-dummy technique used to mask study drugs which were given by separate IV sites using flow rates and concentrations according to each patient's body mass.
Participants	Eligible patients had a diagnosed spinal cord injury, gave consent, were randomized within 12 hours of injury, 13 years or older, and met other specified clinical and study criteria. In all 487 patients randomized to three arms and analysis followed intention-to-treat principle.
Interventions	Treatment arm 1: (n=162) Methylprednisolone bolus of 30 mg/kg body weight followed by 5.4 mg/kg per hour for 23 hours. Treatment arm 2: (n=154) Naloxone bolus of 5.4 mg/kg of body weight followed by 4.0 mg/kg per hour for 23 hours. Treatment arm 3: (n=171) Placebo given by bolus and infusion using double-dummy technique.
Outcomes	Neurological function examined six weeks, six months and one year after injury using categorical and continuous scales to assess motor function, pin and light touch sensation. Morbidity evaluated at same times and included all outcomes studied in earlier (1984) NASCIS trial. Mortality assessed to 1 year after injury. All outcomes assessed blind.
Notes	This trial is often referred to as NASCIS 2 (The second National Acute Spinal Cord Injury Study).

Risk of bias

Bias	Authors' judgement	Support for judgement

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bracken 1990/93 *(Continued)*

Random sequence generation (selection bias)	Low risk	See Methods
Allocation concealment (selection bias)	Low risk	See Methods
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients, caregivers and statistical analysts blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Patients and caregivers blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	98% follow-up at 6 weeks and 96% at 6 months, 100% survival analysis
Selective reporting (reporting bias)	Low risk	Outcomes prespecified in protocol
Other bias	Low risk	Subgroups prespecified in protocol

Bracken 1997/98

Methods	Multi-center (n=16) double-blind randomized trial. After ascertaining eligibility a 24-hour telephone number called to randomize. Three treatment arms in blocks of 9 (3 each arm per center). Double-dummy techniques used to mask study drug which were given by IV using infusion rates and dose schedules according to each patient's body mass.
Participants	Eligible patients had diagnosed spinal cord injury, gave consent, were randomized within 6 hours of injury to begin treatment within 8 hours, were 13 years or older, and met other specified clinical and study criteria. In all 499 patients were randomized (485 planned) to three arms and analysis used intent-to-treat and compliers (N=461) groups.
Interventions	All patients received an IV bolus of methylprednisolone (30 mg/kg) before randomization. Patients in 24h regimen (N=166) received methylprednisolone infusion of 5.4 mg/kg/h for 24h, those in the 48h methylprednisolone group (n=167) received an infusion of 5.4 mg/kg/h for 48h, and those in a third group (n=166) received a 2.5 mg/kg bolus infusion of tirilazad mesylate every 6h for 48h.
Outcomes	Motor function change between initial presentation and at 6 weeks and 6 months after injury, and functional independence measure (FIM) assessed at 6 weeks and six months and one year. Morbidity evaluated at six weeks and six months and included all outcomes assessed in earlier (1984 and 1990) NASCIS trials. Mortality assessed at six months and at one year post injury. All outcomes assessed blind.
Notes	This trial is often referred to as NASCIS 3 (the third National Acute Spinal Cord Injury Study). Methylprednisolone is the sodium succinate preparation.

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	See Methods

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bracken 1997/98 *(Continued)*

Allocation concealment (selection bias)	Low risk	See Methods
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients, caregivers and statistical analysts blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Patients and caregivers blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	97% follow-up at 6 weeks and 94% at 6 months, 100% survival analysis
Selective reporting (reporting bias)	Low risk	Outcomes prespecified in protocol
Other bias	Low risk	Subgroups prespecified in protocol

Glasser 1993

Methods	Randomized single (patient) blind trial. Method of randomization not specified.
Participants	Patients undergoing lumbar discetomy presenting with radicular symptoms and radiographically confirmed herniated nucleus pulposus.
Interventions	1) 160 mg IM Depo-Medrol and 250 mg MPPS at start of procedure. Macerated fat graft soaked in 80 mg Depo-Medrol placed over affected nerve root after discetomy. 30 ml 0.25% bupivacaine infiltrated to paraspinal muscles during closure (N=12). 2) Bupivacaine procedure only (N=10). 3) No corticoids or bupivacaine (N=10).
Outcomes	Length of hospital stay; postpartum narcotic analgesia; back and radicular pain on post-op day 1.
Notes	Depo-Medrol is methylprednisolone acetate. MPPS is methylprednisolone sodium succinate. This study may largely be assessing nerve roots rather than acute spinal cord injuty.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization methods not stated
Allocation concealment (selection bias)	Unclear risk	Randomization methods not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	The study was not blinded

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Glasser 1993 *(Continued)*

Blinding of outcome assessment (detection bias) All outcomes	High risk	The study was not blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	72% of patients were followed-up
Selective reporting (reporting bias)	Unclear risk	Protocol not seen
Other bias	Unclear risk	None observed

Matsumoto 2001

Methods	Single center randomized double blind trial. Method of randomization not specified.
Participants	In all 46 patients with cervical spine injury. Exclusions were only nerve root injuries, cauda equina and gunshot victims.
Interventions	Treatment arm 1: (n=23) MPSS given according to NASCIS 2 protocol. Treatment arm 2: (n=23) placebo (no details of placebo provided).
Outcomes	Efficacy not studied. Complications assessed 8 weeks after injury.
Notes	Some evidence for MPSS group to be more severely injured.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization methods not stated
Allocation concealment (selection bias)	Unclear risk	Randomization methods not stated
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients, caregivers and statistical analysts blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Patients and caregivers blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	100% follow-up
Selective reporting (reporting bias)	Unclear risk	Only selected data on complications reported
Other bias	Unclear risk	None observed

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Otani 1994

Methods	Patients allocated "by envelope method" and so assumed to be randomized. Blinding is not assumed since no placebo group.
Participants	Multicenter trial in Japan including 15 neurosurgery, 27 orthopedic and 11 emergency centers. Inclusion criteria: diagnosis of loss of motor or sensory function from spinal cord injury; could receive treatment within 8 hours of injury; 16-25 years of age; obtained informed consent; available for 6 month follow-up. Excluded: root involvement or cauda equina only; serious co-morbidity; corticosteroid use > 100 mg MPSS or equivalent before randomization; other prespecified clinical criteria. In all 158 patients randomized (82 MPSS, 76 control) of which 81 and 70, and 70 and 47 entered the safety and efficacy analyses respectively. Reasons for drop-out are tabulated. It appears as if largest exclusions were for control patients. Baseline differentials suggest this occurred most frequently in severely injured controls.
Interventions	1. Treated group: MPSS as bolus of 30 mg/kg for 15 mins by infusion, 45 mins pause then 23 hr maintenance infusion by 5.4 mg/kg. (NB this is an exact replication of the NASCIS 2 MPSS protocol, see Bracken et al 1990). No other corticosteroid therapy. 2. Control group: standard treatment without any corticosteroid therapy. No placebo given. NB surgery appears to have been given as necessary but this is not entirely clear from text.
Outcomes	Neurological follow-up was at 24 and 48 hrs, one and six weeks, three and six months. Motor function, pin and light touch sensation were assessed using NASCIS 2 criteria and Frankel's classification (at 6 months). Urinary function and sphincter control were evaluated. A global improvement assessment was also used. A large number of laboratory values and vital signs were measured.
Notes	A translation of this paper from the original Japanese has been provided by Pharmacia Upjohn Inc. Copies of the English translation are available from the editor of this review.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	See Methods
Allocation concealment (selection bias)	Low risk	See Methods
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding in this study - control is conventional therapy
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding in this study - done by attending doctor
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	74% follow-up at final six month outcome assessment
Selective reporting (reporting bias)	Low risk	Published reports concur with protocol expectations (reviewer has copy of protocol)
Other bias	Unclear risk	Upjohn directly funded the study

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Petitjean 1998

Methods	Single center trial. Randomization methods: two numbers given each treatment and followed "table de permutation au hasard" and balanced every eight patients. Administration of intervention not masked.
Participants	Eligible patients had a diagnosed spinal cord injury, gave consent, were hospitalized within 8h of injury, were aged 16 to 64, and met other clinical criteria.
Interventions	1) Methylprednisolone bolus of 30mg/kg over 1h followed by 5.4mg/kg/h for 23h (N=27). 2) Nimodipine 0.015mg/kg/h over 2h followed by 0.03mg/kg/h for 7days if MABP > 60mgHg (N=27). 3) Both of the above treatments given concurrently (N=27). 4) No pharmacologic treatment (N=25).
Outcomes	Neurological examination using ASIA criteria at admission and 1year after injury. Outcome assessed blind.
Notes	A translation of this paper from the original French is available from the Cochrane Injuries review Group. ASIA and NASCIS neurological examinations are identical except for one additional segment measured in NASCIS. Additional information obtained from author but N's slightly larger in published report.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization methods not stated but blocked at 8
Allocation concealment (selection bias)	Unclear risk	Randomization methods not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding in this study
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding in this study
Incomplete outcome data (attrition bias) All outcomes	Low risk	94% follow-up at 1 year final outcome assessment
Selective reporting (reporting bias)	Unclear risk	Protocol not seen
Other bias	Unclear risk	Protocol not seen

Pettersson 1998

Methods	Randomized double blind trial. Method of randomization not specified.
Participants	Men and women with whiplash injury Grade 2 and 3 by Quebec criteria and enrolled within 8 hours of injury.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Pettersson 1998 *(Continued)*

Interventions	(1) Methylprednisolone bolus of 30 mg/kg for 15 min, wait 45 min, then 5.4 mg/kg/h for 23h (N=20). (2) Placebo (N=20).
Outcomes	Repeated neurological examinations, VAS-scales and pain sketch form at baseline, 2 and 6 weeks and 6 months after injury. Number of sick days. Outcomes assessed blind.
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomized by pharmacist
Allocation concealment (selection bias)	Low risk	Randomized by pharmacist
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients and caregivers blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Patients and caregivers blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	100% follow-up at final 6 month assessment
Selective reporting (reporting bias)	Unclear risk	Protocol not seen
Other bias	Unclear risk	Protocol not seen

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Kiwerski 1992	Patients not randomized to treatment.
Pointillart 2000	Duplicate publication of Petitjean 1998. Translated into English, very minor changes to table 3 (numbers instead of per cent), and no reference in this paper to original French version. Change in first authorship.
Yokota 1995	Patients not randomized to treatment. An English translation of this study is available from the Cochrane Injuries Group.

DATA AND ANALYSES

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison 1. Moderate vs low-dose MPSS, 10-day regimen

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Motor function at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.1 Motor function at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Motor function at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 Motor function at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Motor function at six weeks, six months and one year: <8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2.1 Motor function at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Motor function at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Motor function at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Pinprick sensation at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3.1 Pinprick sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Pinprick sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.3 Pinprick sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 Pinprick sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Pinprick sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 Pinprick sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Touch sensation at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 Touch sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
5.2 Touch sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.3 Touch sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Touch sensation at six weeks, six months and one year: <8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.1 Touch sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 Touch sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.3 Touch sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 All-cause mortality, <210 days	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
8 Wound infection at six weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
9 GI haemorrhage at six weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
10 Sepsis at six weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

Analysis 1.1. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.1.1 Motor function at six weeks						
Bracken 1984/85	125	8.2 (15.2)	133	8.8 (16.3)		-0.6[-4.44,3.24]
1.1.2 Motor function at six months						
Bracken 1984/85	91	13.2 (14.8)	88	14.1 (15.8)		-0.9[-5.38,3.58]
1.1.3 Motor function at one year						
Bracken 1984/85	115	12 (13.4)	108	11.5 (13.7)		0.46[-3.11,4.03]



Analysis 1.2. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 2 Motor function at six weeks, six months and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.2.1 Motor function at six weeks						
Bracken 1984/85	61	7.4 (11.8)	68	5.7 (12.3)		1.7[-2.46,5.86]



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.2.2 Motor function at six months						
Bracken 1984/85	50	13.4 (14.2)	53	8.4 (12.7)		5[-0.21,10.21]
1.2.3 Motor function at one year						
Bracken 1984/85	54	14.2 (16.7)	58	10.4 (14.8)		3.8[-2.06,9.66]



Analysis 1.3. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.3.1 Pinprick sensation at six weeks						
Bracken 1984/85	125	7.1 (18.2)	133	6.2 (15.9)		0.9[-3.28,5.08]
1.3.2 Pinprick sensation at six months						
Bracken 1984/85	91	9.4 (14.3)	88	9.9 (15)		-0.5[-4.79,3.79]
1.3.3 Pinprick sensation at one year						
Bracken 1984/85	115	6.8 (11.7)	108	8.4 (11.9)		-1.67[-4.76,1.42]



Analysis 1.4. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.4.1 Pinprick sensation at six weeks						
Bracken 1984/85	60	6 (14.1)	69	3.3 (7.4)		2.7[-1.27,6.67]
1.4.2 Pinprick sensation at six months						
Bracken 1984/85	50	7.1 (11.2)	53	4.7 (10)		2.4[-1.71,6.51]
1.4.3 Pinprick sensation at one year						
Bracken 1984/85	54	8.6 (12.2)	58	5.5 (10.4)		3.1[-1.11,7.31]



Analysis 1.5. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.5.1 Touch sensation at six weeks						



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
Bracken 1984/85	125	7.4 (16.1)	133	7 (15.3)		0.4[-3.43,4.23]
1.5.2 Touch sensation at six months						
Bracken 1984/85	91	10.4 (14.5)	88	10.4 (14.5)		0[-4.26,4.26]
1.5.3 Touch sensation at one year						
Bracken 1984/85	114	7.6 (10.9)	107	7.3 (11.3)		0.25[-2.68,3.18]



Analysis 1.6. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
1.6.1 Touch sensation at six weeks						
Bracken 1984/85	60	7.3 (12.3)	69	4 (9.4)		3.3[-0.52,7.12]
1.6.2 Touch sensation at six months						
Bracken 1984/85	50	8.7 (11.3)	52	4.6 (10.1)		4.1[-0.06,8.26]
1.6.3 Touch sensation at one year						
Bracken 1984/85	53	10.6 (11.6)	58	7.1 (10.4)		3.5[-0.61,7.61]



Analysis 1.7. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 7 All-cause mortality, <210 days.

Study or subgroup	n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1984/85	19/165	13/165		1.46[0.75,2.86]



Analysis 1.8. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 8 Wound infection at six weeks.

Study or subgroup	n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1984/85	14/165	4/165		3.5[1.18,10.41]



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 1.9. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 9 GI haemorrhage at six weeks.

Study or subgroup	n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1984/85	15/165	13/165		1.15[0.57,2.35]



Analysis 1.10. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 10 Sepsis at six weeks.

Study or subgroup	n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1984/85	13/165	15/165		0.87[0.43,1.76]



Comparison 2. High-dose MPSS vs none, 24-hour regimen

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Motor function at six weeks, six months and one year: all patients	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 Motor function at six weeks	1	306	Mean Difference (IV, Fixed, 95% CI)	1.23 [-1.08, 3.54]
1.2 Motor function at six months	2	414	Mean Difference (IV, Fixed, 95% CI)	0.85 [-1.79, 3.49]
1.3 Motor function at one year	2	335	Mean Difference (IV, Fixed, 95% CI)	-1.17 [-4.80, 2.47]
2 Motor function at six weeks, six months, and one year: <8 hours to treatment	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Motor function at six weeks	1	136	Mean Difference (IV, Fixed, 95% CI)	3.47 [0.02, 6.92]
2.2 Motor function at six months	2	250	Mean Difference (IV, Fixed, 95% CI)	4.44 [0.96, 7.93]
2.3 Motor function at one year	2	177	Mean Difference (IV, Fixed, 95% CI)	4.17 [-0.27, 8.61]
2.4 Motor function at final (six-month or one-year) outcome	3	294	Mean Difference (IV, Fixed, 95% CI)	4.06 [0.58, 7.55]
3 Pinprick sensation at six weeks, six months and one year: all pa-tients	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 Pinprick sensation at six weeks	1	301	Mean Difference (IV, Fixed, 95% CI)	1.88 [-0.23, 3.99]
3.2 Pinprick sensation at six months	1	295	Mean Difference (IV, Fixed, 95% CI)	3.37 [0.74, 6.00]

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
3.3 Pinprick sensation at one year	2	334	Mean Difference (IV, Fixed, 95% CI)	0.18 [-2.66, 3.02]
4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Pinprick at Six Weeks	1	136	Mean Difference (IV, Fixed, 95% CI)	3.02 [-0.14, 6.18]
4.2 Pinprick at Six Months	1	133	Mean Difference (IV, Fixed, 95% CI)	4.82 [0.91, 8.73]
4.3 Pinprick at One Year	2	177	Mean Difference (IV, Fixed, 95% CI)	2.32 [-1.73, 6.37]
5 Touch sensation at six weeks, six months and one year: All pa-tients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 Touch Sensation at Six Weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Touch Sensation at Six Months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.3 Touch Sensation at One Year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Touch sensation at six weeks, six months and one year: <8 hours to treatment	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 Touch Sensation at Six Weeks	1	136	Mean Difference (IV, Fixed, 95% CI)	3.79 [0.28, 7.30]
6.2 Touch Sensation at Six Months	1	133	Mean Difference (IV, Fixed, 95% CI)	4.59 [0.43, 8.75]
6.3 Touch Sensation at One Year	2	177	Mean Difference (IV, Fixed, 95% CI)	3.35 [-0.82, 7.53]
7 All-cause mortality <180 days	3	530	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.24, 1.25]
8 Wound infection at 6 weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
9 GI haemorrhage at 6 weeks	2	379	Risk Ratio (M-H, Fixed, 95% CI)	2.18 [0.80, 5.93]

Analysis 2.1. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.1.1 Motor function at six weeks							
Bracken 1990/93	148	9.4 (10.3)	158	8.2 (10.3)		100%	1.23[-1.08,3.54]
Subtotal ***	**148**		**158**			**100%**	**1.23[-1.08,3.54]**
Heterogeneity: Not applicable							



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Test for overall effect: Z=1.04(P=0.3)							
2.1.2 Motor function at six months							
Bracken 1990/93	144	13.3 (13.2)	153	13.3 (13.1)		77.97%	-0.01[-3,2.98]
Otani 1994	70	14.2 (15)	47	10.3 (15.4)		22.03%	3.9[-1.73,9.53]
Subtotal ***	**214**		**200**			**100%**	**0.85[-1.79,3.49]**
Heterogeneity: Tau²=0; Chi²=1.44, df=1(P=0.23); I²=30.71%							
Test for overall effect: Z=0.63(P=0.53)							
2.1.3 Motor function at one year							
Bracken 1990/93	138	12.5 (16.1)	147	13.3 (16.3)		93.65%	-0.86[-4.62,2.9]
Petitjean 1998	27	18 (27.4)	23	23.7 (24.6)		6.35%	-5.7[-20.12,8.72]
Subtotal ***	**165**		**170**			**100%**	**-1.17[-4.8,2.47]**
Heterogeneity: Tau²=0; Chi²=0.41, df=1(P=0.52); I²=0%							
Test for overall effect: Z=0.63(P=0.53)							
Test for subgroup differences: Chi²=1.22, df=1 (P=0.54), I²=0%							



Analysis 2.2. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 2 Motor function at six weeks, six months, and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.2.1 Motor function at six weeks							
Bracken 1990/93	66	10.6 (10.2)	70	7.2 (10.3)		100%	3.47[0.02,6.92]
Subtotal ***	**66**		**70**			**100%**	**3.47[0.02,6.92]**
Heterogeneity: Not applicable							
Test for overall effect: Z=1.97(P=0.05)							
2.2.2 Motor function at six months							
Bracken 1990/93	65	16 (13.1)	68	11.2 (13)		61.73%	4.78[0.34,9.22]
Otani 1994	70	14.2 (15)	47	10.3 (15.4)		38.27%	3.9[-1.73,9.53]
Subtotal ***	**135**		**115**			**100%**	**4.44[0.96,7.93]**
Heterogeneity: Tau²=0; Chi²=0.06, df=1(P=0.81); I²=0%							
Test for overall effect: Z=2.5(P=0.01)							
2.2.3 Motor function at one year							
Bracken 1990/93	62	17.2 (13.4)	65	12 (13.4)		90.51%	5.2[0.53,9.87]
Petitjean 1998	27	18 (27.4)	23	23.7 (24.6)		9.49%	-5.7[-20.12,8.72]
Subtotal ***	**89**		**88**			**100%**	**4.17[-0.27,8.61]**
Heterogeneity: Tau²=0; Chi²=1.99, df=1(P=0.16); I²=49.68%							
Test for overall effect: Z=1.84(P=0.07)							
2.2.4 Motor function at final (six-month or one-year) outcome							
Otani 1994	70	14.2 (15)	47	10.3 (15.4)		38.33%	3.9[-1.73,9.53]
Bracken 1990/93	62	17.2 (13.4)	65	12 (13.4)		55.82%	5.2[0.53,9.87]
Petitjean 1998	27	18 (27.4)	23	23.7 (24.6)		5.85%	-5.7[-20.12,8.72]
Subtotal ***	**159**		**135**			**100%**	**4.06[0.58,7.55]**
Heterogeneity: Tau²=0; Chi²=1.99, df=2(P=0.37); I²=0%							



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Test for overall effect: Z=2.28(P=0.02)							
Test for subgroup differences: Chi^2=0.16, df=1 (P=0.98), I^2=0%							



Analysis 2.3. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.3.1 Pinprick sensation at six weeks							
Bracken 1990/93	146	6.7 (9.4)	155	4.8 (9.3)		100%	1.88[-0.23,3.99]
Subtotal ***	**146**		**155**			**100%**	**1.88[-0.23,3.99]**
Heterogeneity: Not applicable							
Test for overall effect: Z=1.75(P=0.08)							
2.3.2 Pinprick sensation at six months							
Bracken 1990/93	143	10 (11.6)	152	6.6 (11.5)		100%	3.37[0.74,6]
Subtotal ***	**143**		**152**			**100%**	**3.37[0.74,6]**
Heterogeneity: Not applicable							
Test for overall effect: Z=2.51(P=0.01)							
2.3.3 Pinprick sensation at one year							
Bracken 1990/93	138	7.8 (12.3)	146	7.6 (12.3)		98.12%	0.18[-2.69,3.05]
Petitjean 1998	27	11.6 (35.6)	23	11.6 (38.6)		1.88%	0[-20.72,20.72]
Subtotal ***	**165**		**169**			**100%**	**0.18[-2.66,3.02]**
Heterogeneity: Tau^2=0; Chi^2=0, df=1(P=0.99); I^2=0%							
Test for overall effect: Z=0.12(P=0.9)							
Test for subgroup differences: Chi^2=2.62, df=1 (P=0.27), I^2=23.53%							



Analysis 2.4. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.4.1 Pinprick at Six Weeks							
Bracken 1990/93	66	7.8 (9.4)	70	4.8 (9.4)		100%	3.02[-0.14,6.18]
Subtotal ***	**66**		**70**			**100%**	**3.02[-0.14,6.18]**
Heterogeneity: Not applicable							
Test for overall effect: Z=1.87(P=0.06)							
2.4.2 Pinprick at Six Months							
Bracken 1990/93	65	11.4 (11.6)	68	6.6 (11.5)		100%	4.82[0.91,8.73]
Subtotal ***	**65**		**68**			**100%**	**4.82[0.91,8.73]**
Heterogeneity: Not applicable							
Test for overall effect: Z=2.41(P=0.02)							



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.4.3 Pinprick at One Year							
Bracken 1990/93	62	10.8 (11.9)	65	8.4 (11.9)		96.18%	2.41[-1.72,6.54]
Petitjean 1998	27	11.6 (35.6)	23	11.6 (38.6)		3.82%	0[-20.72,20.72]
Subtotal ***	**89**		**88**			**100%**	**2.32[-1.73,6.37]**
Heterogeneity: Tau²=0; Chi²=0.05, df=1(P=0.82); I²=0%							
Test for overall effect: Z=1.12(P=0.26)							
Test for subgroup differences: Chi²=0.83, df=1 (P=0.66), I²=0%							



Analysis 2.5. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 5 Touch sensation at six weeks, six months and one year: All patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
2.5.1 Touch Sensation at Six Weeks						
Bracken 1990/93	146	6.1 (10.4)	154	3.9 (10.3)		2.17[-0.17,4.51]
2.5.2 Touch Sensation at Six Months						
Bracken 1990/93	142	8.7 (12.2)	152	5.9 (12.2)		2.88[0.1,5.66]
2.5.3 Touch Sensation at One Year						
Bracken 1990/93	137	7.5 (12.4)	145	6.9 (12.4)		0.69[-2.21,3.59]



Analysis 2.6. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
2.6.1 Touch Sensation at Six Weeks							
Bracken 1990/93	66	6.3 (10.4)	70	2.5 (10.5)		100%	3.79[0.28,7.3]
Subtotal ***	**66**		**70**			**100%**	**3.79[0.28,7.3]**
Heterogeneity: Not applicable							
Test for overall effect: Z=2.12(P=0.03)							
2.6.2 Touch Sensation at Six Months							
Bracken 1990/93	65	8.9 (12.3)	68	4.3 (12.2)		100%	4.59[0.43,8.75]
Subtotal ***	**65**		**68**			**100%**	**4.59[0.43,8.75]**
Heterogeneity: Not applicable							
Test for overall effect: Z=2.16(P=0.03)							
2.6.3 Touch Sensation at One Year							
Bracken 1990/93	62	9.4 (12.4)	65	6 (12.3)		94.76%	3.38[-0.91,7.67]
Petitjean 1998	27	16.2 (32.4)	23	13.3 (33.2)		5.24%	2.9[-15.36,21.16]
Subtotal ***	**89**		**88**			**100%**	**3.35[-0.82,7.53]**
Heterogeneity: Tau²=0; Chi²=0, df=1(P=0.96); I²=0%							
Test for overall effect: Z=1.57(P=0.12)							



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Test for subgroup differences: Chi²=0.17, df=1 (P=0.92), I²=0%							



Analysis 2.7. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 7 All-cause mortality <180 days.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
Bracken 1990/93	7/162	12/171		78.39%	0.62[0.25,1.53]
Matsumoto 2001	0/23	0/23			Not estimable
Otani 1994	1/81	3/70		21.61%	0.29[0.03,2.71]
Total (95% CI)	**266**	**264**		**100%**	**0.54[0.24,1.25]**
Total events: 8 (Treatment), 15 (Control)					
Heterogeneity: Tau²=0; Chi²=0.38, df=1(P=0.54); I²=0%					
Test for overall effect: Z=1.43(P=0.15)					



Analysis 2.8. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 8 Wound infection at 6 weeks.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1990/93	12/162	6/171		2.11[0.81,5.49]



Analysis 2.9. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 9 GI haemorrhage at 6 weeks.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
Bracken 1990/93	7/162	5/171		90.68%	1.48[0.48,4.56]
Matsumoto 2001	4/23	0/23		9.32%	9[0.51,158.17]
Total (95% CI)	**185**	**194**		**100%**	**2.18[0.8,5.93]**
Total events: 11 (Treatment), 5 (Control)					
Heterogeneity: Tau²=0; Chi²=1.4, df=1(P=0.24); I²=28.38%					
Test for overall effect: Z=1.52(P=0.13)					



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison 3. High-dose MPSS for 48 hours vs 24 hours

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Motor function at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.1 Motor function at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Motor function at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 Motor function at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Motor function at six weeks, six months and one year: 3-8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2.1 Motor function at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Motor function at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Motor function at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Pinprick sensation at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3.1 Pinprick sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Pinprick sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.3 Pinprick sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Pinprick sensation at six weeks, six months and one year: 3-8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 Pinprick sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Pinprick sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 Pinprick sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Touch sensation at six weeks, six months and one year: all patients	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 Touch sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
5.2 Touch sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.3 Touch sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Touch sensation at six weeks, six months and one year: 3-8 hours to treatment	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.1 Touch sensation at six weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 Touch sensation at six months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.3 Touch sensation at one year	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Severe pneumonia at 6 weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
8 Severe sepsis at 6 weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
9 Mortality at 1 year	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

Analysis 3.1. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 1 Motor function at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.1.1 Motor function at six weeks						
Bracken 1997/98	154	11.8 (15.4)	151	9 (15.2)		2.81[-0.62,6.24]
3.1.2 Motor function at six months						
Bracken 1997/98	149	16.8 (17.9)	142	13.4 (16.1)		3.37[-0.54,7.28]
3.1.3 Motor function at one year						
Bracken 1997/98	141	17.8 (18.4)	145	15.4 (16.9)		2.35[-1.75,6.45]



Analysis 3.2. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 2 Motor function at six weeks, six months and one year: 3-8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.2.1 Motor function at six weeks						
Bracken 1997/98	93	12.5 (16.2)	81	7.6 (13.4)		4.9[0.51,9.29]
3.2.2 Motor function at six months						



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
Bracken 1997/98	89	17.6 (19)	76	11.2 (14)		6.46[1.41,11.51]
3.2.3 Motor function at one year						
Bracken 1997/98	82	19 (19.6)	77	13.7 (14.1)		5.28[-0,10.56]



Analysis 3.3. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.3.1 Pinprick sensation at six weeks						
Bracken 1997/98	154	8.6 (13.7)	151	7.2 (12.5)		1.39[-1.55,4.33]
3.3.2 Pinprick sensation at six months						
Bracken 1997/98	149	9.2 (14)	142	8.8 (12)		0.42[-2.57,3.41]
3.3.3 Pinprick sensation at one year						
Bracken 1997/98	141	10.4 (13.8)	145	10 (13)		0.4[-2.7,3.5]



Analysis 3.4. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 4 Pinprick sensation at six weeks, six months and one year: 3-8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.4.1 Pinprick sensation at six weeks						
Bracken 1997/98	93	9.8 (16)	81	6.8 (11)		3.03[-1.01,7.07]
3.4.2 Pinprick sensation at six months						
Bracken 1997/98	89	9.7 (15.1)	76	8.1 (12.4)		1.67[-2.53,5.87]
3.4.3 Pinprick sensation at one year						
Bracken 1997/98	82	10.6 (14.2)	77	9.2 (12.3)		1.4[-2.73,5.53]

Analysis 3.5. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.5.1 Touch sensation at six weeks						
Bracken 1997/98	154	8.6 (14.4)	151	6.9 (12.1)		1.72[-1.26,4.7]

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.5.2 Touch sensation at six months						
Bracken 1997/98	149	9.6 (14.5)	142	8.7 (12.6)		0.89[-2.23,4.01]
3.5.3 Touch sensation at one year						
Bracken 1997/98	141	10.6 (14.5)	145	9.6 (12.2)		1[-2.1,4.1]



Analysis 3.6. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 6 Touch sensation at six weeks, six months and one year: 3-8 hours to treatment.

Study or subgroup	Treatment N	Treatment Mean(SD)	Control N	Control Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
3.6.1 Touch sensation at six weeks						
Bracken 1997/98	92	9.8 (16.6)	78	7.5 (12.7)		2.28[-2.12,6.68]
3.6.2 Touch sensation at six months						
Bracken 1997/98	89	9.8 (14.9)	76	9.5 (13)		0.25[-4.01,4.51]
3.6.3 Touch sensation at one year						
Bracken 1997/98	82	9.6 (13.1)	77	10.3 (14.1)		-0.7[-4.94,3.54]



Analysis 3.7. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 7 Severe pneumonia at 6 weeks.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1997/98	9/154	4/154		2.25[0.71,7.15]



Analysis 3.8. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 8 Severe sepsis at 6 weeks.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1997/98	4/154	1/154		4[0.45,35.38]



Analysis 3.9. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 9 Mortality at 1 year.

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Bracken 1997/98	10/166	9/166		1.11[0.46,2.66]



Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison 4. Methylprednisolone for 23 hours and nimodipine for 7 days

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 One-year motor function improvement score	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2 One-year pinprick sensation improvement score	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 One-year touch sensation improvement score	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

Analysis 4.1. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 1 One-year motor function improvement score.

Study or subgroup	N	Mean(SD)	N	Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
Petitjean 1998	26	15.6 (29.6)	23	23.7 (24.6)		-8.1[-23.28,7.08]



Analysis 4.2. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 2 One-year pinprick sensation improvement score.

Study or subgroup	N	Mean(SD)	N	Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
Petitjean 1998	26	10.6 (36)	23	11.6 (38.6)		-1[-21.98,19.98]



Analysis 4.3. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 3 One-year touch sensation improvement score.

Study or subgroup	N	Mean(SD)	N	Mean(SD)	Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
Petitjean 1998	26	11.5 (35.5)	23	13.3 (33.2)		-1.8[-21.04,17.44]



APPENDICES

Appendix 1. Search strategy

Cochrane Injuries Group Specialised Register (searched 02 August 2011)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#1 ("spinal cord" or spinal-cord* or spine or spinal) and (Broken or break* or fractur* or wound* or trauma* or injur* or damag* or lesion* or contusion* or laceration* or trauma or ischemi*))
#2 paraplegi* or paraparesis or qadriplegi* or quadriparesi* or tetraplegi* or tetraplagi* or tetraparesis
#3 central cord injury syndrome
#4 (myelopathy and (traumatic or post-traumatic))
#5 (steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*)
#6 #1 and #2

Cochrane Central Register of Controlled Trials 2011, issue 3 (*The Cochrane Library*)
#1 paraplegi* or paraparesis
#2 qadriplegi* or quadriparesi*
#3 tetraplegi* or tetraplagi* or tetraparesis
#4 (spine or spinal) near3 (Broken or break* or fracture* or wound* or trauma* or injur* or damag*)
#5 (spinal cord) near3 (contusion or laceration or trauma or injur* or ischemi*)
#6 (central cord injury syndrome)
#7 (myelopathy near3 (traumatic or post-traumatic))
#8 MeSH descriptor Central Cord Syndrome explode all trees
#9 MeSH descriptor Spinal Cord Ischemia explode all trees
#10 MeSH descriptor Spinal Fractures explode all trees
#11 MeSH descriptor Spinal Cord Injuries explode all trees
#12 MeSH descriptor Paraplegia explode all trees
#13 MeSH descriptor Quadriplegia explode all trees
#14 MeSH descriptor Spinal Cord explode all trees with qualifiers: SU,TH
#15 MeSH descriptor Cervical Vertebrae explode all trees with qualifier: IN
#16 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 MeSH descriptor Glucocorticoids explode all trees
#18 MeSH descriptor Steroids explode all trees
#19 steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*
#20 (#17 OR #18 OR #19)
#21 (#16 AND #20)

MEDLINE (Ovid SP) 1948 to July Week 3 2011
1. exp Spinal Cord/su, th [Surgery, Therapy]
2. exp Spinal Cord Injuries/
3. exp Spinal Cord Ischemia/
4. exp Central Cord Syndrome/
5. (myelopathy adj3 (traumatic or post-traumatic)).ab,ti.
6. ((spine or spinal) adj3 (fracture* or wound* or trauma* or injur* or damag*)).ab,ti.
7. (spinal cord adj3 (contusion or laceration or transaction or trauma or ischemia)).ab,ti.
8. central cord injury syndrome.ab,ti.
9. central spinal cord syndrome.ab,ti.
10. exp Cervical Vertebrae/in [Injuries]
11. SCI.ab,ti.
12. exp Paraplegia/
13. exp Quadriplegia/
14. (paraplegi* or quadriplegi* or tetraplegi*).ab,ti.
15. or/1-14
16. exp Glucocorticoids/
17. exp Steroids/
18. (steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*).ab,ti.
19. 16 or 17 or 18
20. 15 and 19
21. randomi?ed.ab,ti.
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. placebo.ab.
25. clinical trials as topic.sh.
26. randomly.ab.
27. trial.ti.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28. 21 or 22 or 23 or 24 or 25 or 26 or 27
29. (animals not (humans and animals)).sh.
30. 28 not 29
31. 20 and 30

EMBASE 1974 to 2011 August (week 17)
1.exp Spinal Cord/su, th [Surgery, Therapy]
2.exp Spinal Cord Injury/
3.exp Spinal Cord Ischemia/
4.exp Central Cord Syndrome/
5.(myelopathy adj3 (traumatic or post-traumatic)).ab,ti.
6.((spine or spinal) adj3 (fracture* or wound* or trauma* or injur* or damag*)).ab,ti.
7.(spinal cord adj3 (contusion or laceration or transaction or trauma or ischemia)).ab,ti.
8.central cord injury syndrome.ab,ti.
9.central spinal cord syndrome.ab,ti.
10.exp Paraplegia/
11.exp Quadriplegia/
12.(paraplegi* or quadriplegi* or tertraplegi*).ab,ti.
13.SCI.ab,ti.
14.or/1-13
15.exp Glucocorticoid/
16.exp Steroid/
17.(steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*).ab,ti.
18.or/15-17
19.14 and 18
20.exp Randomized Controlled Trial/
21.exp controlled clinical trial/
22.randomi?ed.ab,ti.
23.placebo.ab.
24.*Clinical Trial/
25.randomly.ab.
26.trial.ti.
27.20 or 21 or 22 or 23 or 24 or 25 or 26
28.exp animal/ not (exp human/ and exp animal/)
29.27 not 28
30.19 and 29

ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to Aug 2011
ISI Web of Science: Conference Proceedings Citation Index- Science (CPCI-S) 1990 to Aug 2011
#1 Topic=((“spinal cord” or spinal-cord* or spine or spinal) NEAR (Broken or break* or fractur* or wound* or trauma* or injur* or damag* or lesion* or contusion* or laceration* or trauma or ischemi*)) OR Topic=(paraplegi* or paraparesis or qadriplegi* or quadriparesi* or tetraplegi* or tetraplagi* or tetraparesis) OR Topic=("central cord injury syndrome") OR Topic=((spine or spinal) NEAR (myelopathy NEAR (traumatic or post-traumatic)))
#2 Topic=((steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*))
#3 Topic=((clinical OR control* OR placebo OR random*) NEAR (trial* or group* or study or studies or placebo or controlled)) NOT Topic=(ANIMAL*)
#4 #1 AND #2 AND #3

PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 04 August 2011: limit: added to PubMed in the last 90 days)
#1 (“spinal cord” or spinal-cord* or spine or spinal) and (Broken or break* or fractur* or wound* or trauma* or injur* or damag* or lesion* or contusion* or laceration* or trauma or ischemi*))
#2 paraplegi* or paraparesis or qadriplegi* or quadriparesi* or tetraplegi* or tetraplagi* or tetraparesis
#3 central cord injury syndrome
#4 (spine or spinal) and (myelopathy and (traumatic or post-traumatic))
#5 #1 or #2 or #3 or #4
#6 (steroid* or glucocorticoid* or prednisolone* or betamethasone* or cortisone* or dexamethasone* or hydrocortisone* or methylprednisolone* or prednisone* or triamcinolone* or corticosteroid*)
#7 #5 and #6
#8 ((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab]) OR (trial[ti]) OR ("Clinical Trials as Topic"[MeSH Major Topic])) NOT (("Animals"[Mesh]) NOT ("Humans"[Mesh] AND "Animals"[Mesh]))

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#9 #7 and #8

F E E D B A C K

Steroids for acute spinal cord injury

Summary

Please note that this comment, and the subsequent reply from the reviewer, was originally about the first version of this review (Pharmacology in acute spinal cord injury). The review has subsequently been revised to the present version (Steroids for acute spinal cord injury).

Summary of comments and criticisms.

The author of the criticism refers to the papers by Coleman et al 2000, and Hurlbert RJ which disagree with the conclusions of this review. He would like the following points addressed (each comment has a number with a corresponding response from the reviewers in the reply section below):

1. "NASCIS II" implied that there was a positive result in the primary efficacy analysis for the entire 487 patient sample. However, this analysis was in fact negative. A positive result was only found in a secondary analysis of a small subgroup (62 + 67 patients) splitting the sample before and after 8 hours.

2. The placebo group treated before 8 hours did poorly, not only when compared with the methylprednisolone group treated before 8 hours, but even when compared with the placebo group treated after 8 hours. Thus the positive result may have been caused by a weakness in the control group rather than any strength of methylprednisolone.

3. Most of the combined improvement from all patients in the subgroup (62 + 67 patients) was due to differences in the changes in the patients with incomplete lesions. This comparison involved only 22 patients in the methylprednisolone group and 24 patients in the placebo group.

4. The NASCIS II and III reports embody specific choices of statistical methods that have strongly shaped the reporting of results but have not been adequately challenged or even explained.

5. In NASCIS III, a randomization imbalance occurred that allocated a disproportionate number of patients with no motor deficit (and therefore no chance for recovery) to the lower dose control group. When this imbalance is controlled for, much of the superiority of the higher dose group seems to disappear.

6. Perhaps one half of the NASCIS III sample may have had at most a minor deficit. Thus, we do not know whether the results of these studies reflect the severely injured population to which they have been applied.

7. The numbers, tables, and figures in the published reports are scant and are inconsistently defined, making it impossible even for professional statisticians to duplicate the analyses, to guess the effect of changes in assumptions, or to supply the missing parts of the picture.

8. Nonetheless, even 9 years after NASCIS II, the primary data have not been made public.

9. The reporting of the NASCIS studies has fallen short of the guidelines of the ICH/FDA, and of the Evidence-based Medicine Group.

10. Despite the lucrative "off label" markets for methylprednisolone in Spinal Cord Injury, no Food and Drug Association indication has been obtained, and there has been no public process of validation.

11. These shortcomings have denied physicians the chance to use confidently a drug that many were enthusiastic about and have left them in an intolerably ambiguous position in their therapeutic choices, in their legal exposure, and in their ability to perform further research to help their patients.

12. Animal studies of the effect of Methylprednisolone and the human studies are different, and little work has been done to relate them explicitly. It is simply not true that the NASCIS studies either strongly confirm or are strongly confirmed by the animal studies.

In conclusion the use of methylprednisolone administration in the treatment of acute SCI is not proven as a standard of care, nor can it be considered a recommended treatment. Evidence of the drug's efficacy and impact is weak and may only represent random events. In the strictest sense, 24-hour administration of methylprednisolone must still be considered experimental for use in clinical SCI. Forty-eight-hour therapy is not recommended. These conclusions are important to consider in the design of future trials and in the medico-legal arena.

References:

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990 May 17;322(20):1405-11.

Bracken MB, Shepard MJ, Holford TR, et al Administration of Methylprednisolone for 24 or 48 hours or Tirilazad Mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. JAMA 1997;277:1597-1604.

Coleman WP, Benzel D, Cahill DW, Ducker T, Geisler F, Green B et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord. 2000 Jun;13(3):185-99.

Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000 Jul;93(1 Suppl):1-7.

Reply

Detailed responses to the comments reflected in the Criticism have been published elsewhere (1,2) and should be consulted by the interested reader.

1. The primary NASCIS 2 report (3) clearly stated that no benefit of methylprednisolone (MP) was observed in the total study group. In the a priori analysis of patients treated relatively quickly after injury (within 8 hours which was the modal time from injury to initiating therapy, and the only dichotomy analysed) patients treated with MP recovered significantly better than placebo treated patients. Examination of drug effect as a function of time to injury was a major hypothesis in the design of both NASCIS 2 and 3.

2. The comparison of placebo treated patients before versus after eight hours is not a randomized comparison and there is no reason to expect that these patients would be similar. The time taken to initiate therapy was largely a function of how quickly patients were admitted to hospital and there are many reasons why this may vary by severity of injury. The only valid comparisons for analysis are the ones reported, ie. comparisons of treatment (which was randomized) within the early and late time periods.

3. Statistically significant improvement in MP treated patients was observed and reported in both neurologically complete and incomplete patients as assessed in the emergency department.

4. The statistical procedure used to analyze NASCIS 2 and 3 was primarily analysis of covariance which is a standard form of analysis for randomized controlled trials. This methodology is described in any standard text.

5. In NASCIS 3 an imbalance at randomization was reported (4, table 2) which allocated somewhat more severely injured patients to Tiralazad mesylate. There was also a non-significant baseline difference in the two MP groups. Baseline neurological function was controlled in all statistical analyses and, as expected, the multivariate analysis of the two MP groups showed reduced improvement differences when the baseline differences were taken into account. These "controlled" analyses form the primary published results.

6. The NASCIS 3 report (4) shows severity of injury of all patients in the trial. Overall, for motor function 35.2% were quadriplegic; 31.0% paraplegic; 13.4% quadriparetic; 4.0% paraparetic and 14.4% normal although all normal motor responses had some sensory loss. After accounting for trial exclusion criteria (gunshot wounds, etc), the study population reflects the pattern of spinal injury seen in hospital emergency departments. Both NASCIS 2 and 3 showed efficacy of MP in severely injured patients, defined as having complete neurological loss below the level of injury.

7. Professional biostatisticians are among the NASCIS investigators and authors, were part of the review process at NEJM and JAMA, and sat on NIH panels overseeing the trials. Standard statistical procedures were used (item 4) and the neurological and functional definitions used are standard criteria promulgated by the American Spinal Injury Association, endorsed by the International Medical Society of Paraplegia, and widely adopted for clinical and research purposes around the world.

8. NASCIS data sets are available to recognized authoritative agencies and groups who submit a proposal describing their intended use of the data and demonstrate that they have the technical, biostatistical and clinical expertise to understand and analyse these complex data sets in an unbiased manner. Since NASCIS investigators continue to be funded by NIH for analyses of NASCIS 2 and 3, there is concern that analyses not be done which pre-empt publication of the same analyses by the initial investigators.

9. The ICH/FDA guidelines were published in 1996 but they enshrined principles and practices that have been evolving for many years. The NASCIS reports, even early ones, clearly meet both the spirit and intent of the recommendations.

10. The NASCIS studies are funded by the United States National Institute of Neurological Disease and Stroke. However, responsibility for seeking an indication for use in spinal injury from national drug regulatory agencies rests with the pharmaceutical company manufacturing the compound, Pharmacia-Upjohn Inc. NASCIS data is available for purposes of seeking regulatory approval of MP in any country. To the best of our knowledge, FDA approval has not been sought but an indication has been sought and obtained in a large number of other countries.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11. Physicians in many countries confidently use MP for spinal cord injury and have done so since 1990. The NASCIS 2 data supporting use has not changed since 1990. Nothing from the NASCIS studies prevents further research in spinal cord injury just as therapeutic discoveries in other areas of medicine do not stop research either. If MP has no benefit, comparing therapies to it should not pose a problem in demonstrating a new drug's superiority. If MP does confer benefit, comparison with it is necessary.

12. Animal studies serve two roles in developing scientific evidence. They prompt testing of therapies in humans after successful trial in animals and they provide biologic plausibility to the human evidence once it has been gathered. The weight of evidence from cat and other models using MP, which led to the initial trials, is strongly supportive of the role of MP (5). New experimental studies of MP in enhancing neuro-regeneration and playing other beneficial roles at the molecular level (6-8) provide further additional evidence of plausibility to support the human trials. This is an extraordinarily difficult but critically important area of human research and it is cause for concern that more trials of MP and other therapies are not being conducted. Currently, primary evidence of efficacy and safety from three trials, and secondary evidence from trials of related clinical conditions and animal studies, as reported in this Cochrane Review, support use of MP in the management of spinal cord injury. There is no other pharmacologic therapy with sufficient evidence to support use at this time.

References

1. Bracken MB, Aldrich EF, Herr DL et al. Clinical measurement, statistical analysis and risk benefit: controversies from trials of spinal injury. J Trauma 2000; 48:558-61.

2. Bracken MB. Methylprednisolone and spinal cord injury. J Neurosurg Spine 2000; 93:175-8.

3. Bracken MB, Shepard MJ, Collins WF et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second national acute spinal cord injury study. New Engl J Med 1990; 322:1405-11.

4. Bracken MB, Shepard MJ, Holford TR et al. Methylprednisolone administered for 24 or 48 hours, or 48 hour tirilazad mesylate, in the treatment of acute spinal cord injury; results of the third national acute spinal cord injury randomized controlled trial. JAMA 1997; 277:1597-1604.

5. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992; 76:13-22.

6. Oudega M, Vargas CA, Weber AB et al. Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci 1999; 11:2453-64.

7. Banik NL, Matzelle D, Terry E et al. A new mechanism of methylprednisolone and other corticoids action demonstrated in vitro: inhibition of a proteinase (calpain) prevents myelin and cytoskeletal protein degradation. Brain Res 1997; 748:205-10.

8. Xu J, Fan G, Chen S et al. Methylprednisolone inhibition of TNF-alpha expression and NF-KB activation after spinal cord injury.

Contributors

Author of comment: Peter Mikkelsen
Author of response: Michael Bracken

Steroids for acute spinal cord injury, 26 July 2018

Summary

Comment from Dr. Paul Hine: "Criticisms of the conduct of this review have appeared in the BMJ (BMJ 2013;346:f3830) and in greater depth by other authors (Evaniew, N., & Dvorak, M. (2016). Cochrane in CORR®: Steroids for Acute Spinal Cord Injury (Review). Clinical Orthopaedics and Related Research, 474(1), 19–24. http://doi.org/10.1007/s11999-015-4601-6)

In short, the concerns raised are that Michael Bracken was allowed to serve as sole reviewer despite having declared financial and non-financial conflicts of interest.

This review should either be updated to respond to these high-profile criticisms, or withdrawn. At present, its continued publication in the library may undermine the reputation of Cochrane."

Cochrane comments system conflict of interest request: Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your comment?
Conflict of interest declaration from Dr. Hine: "I have a non-financial conflict of interest in that I am concerned about under-reporting of non-financial conflicts of interest."

Reply

This review was requested by the Cochrane Collaboration at a time when single author reviews were deemed acceptable. Several subsequent updates found no additional randomized trials had been conducted. The most recent systematic review and clinical guideline

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

on this topic (1), which should be preferentially consulted, draws essentially the same conclusion as the Cochrane review: that the risk of bias is low in the largest trials and that 24 hour treatment of acute spinal cord injury with MPSS, if started within 8 hours of injury, is a treatment option.

1. A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of Methylprednisolone Sodium Succinate.
Fehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, Brodke DS, Burns AS, Chiba K, Dettori JR, Furlan JC, Hawryluk G, Holly LT, Howley S, Jeji T, Kalsi-Ryan S, Kotter M, Kurpad S, Kwon BK, Marino RJ, Martin AR, Massicotte E, Merli G, Middleton JW, Nakashima H, Nagoshi N, Palmieri K, Skelly AC, Singh A, Tsai EC, Vaccaro A, Yee A, Harrop JS. Global Spine J. 2017 Sep;7(3 Suppl):203S-211S. doi: 10.1177/2192568217703085. Epub 2017 Sep 5. PMID: 29164025

Contributors

Author of the comment: Dr. Paul Hine, Liverpool School of Tropical Medicine, UK
Author of the response: Dr. Michael Bracken, Yale University, USA

WHAT'S NEW

Date	Event	Description
3 September 2018	Feedback has been incorporated	A response to feedback is included in the Feedback 2 section.

HISTORY

Protocol first published: Issue 1, 1998
Review first published: Issue 1, 1998

Date	Event	Description
30 August 2012	Review declared as stable	There are no ongoing RCTs in humans, and no new studies have been included in the review since 2004. The search will be updated in 2015.
7 December 2011	New citation required but conclusions have not changed	The search was updated on 2nd August 2011. 531 (after de-duplication) articles were retrieved. Studies were selected for further examination by screening titles and (in about half of the citations) the abstract. There were no new studies meeting the review's inclusion criteria. The results and conclusions of the review are unchanged.
6 December 2011	New search has been performed	The search for studies has been updated to 2 August 2011.
11 September 2008	Amended	Converted to new review format.
1 September 2007	New search has been performed	Searches were last updated in September 2007. An updated search on MEDLINE and CENTRAL was conducted in October 2004. No new studies for inclusion were found. One further excluded study (Yokota 1995) was identified.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

CONTRIBUTIONS OF AUTHORS

The sole author is responsible for the review.

DECLARATIONS OF INTEREST

Professor Bracken was an occasional consultant to Pharmacia & Upjohn Inc and is an author on several of the papers included in this review.

SOURCES OF SUPPORT

Internal sources

- Yale University School of Medicine Department of Epidemiology and Public Health, USA.

External sources

- National Institute Neurological Diseases and Stroke, NIH, USA.

NOTES

The review will be updated in 2019 with a second author, and will be reported according to Cochrane's current MECIR standards.

INDEX TERMS

Medical Subject Headings (MeSH)

Anti-Inflammatory Agents [administration & dosage] [*therapeutic use]; Drug Administration Schedule; Glucocorticoids [administration & dosage] [*therapeutic use]; Methylprednisolone [administration & dosage] [*therapeutic use]; Neuroprotective Agents [administration & dosage] [*therapeutic use]; Nimodipine [administration & dosage] [therapeutic use]; Randomized Controlled Trials as Topic; Spinal Cord Injuries [*drug therapy]

MeSH check words

Humans

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.